Consolidated Portfolio Review Corp’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,693	Closed	-$260K	–	451
2025 Q1	$260K	Sell	12,693 -123	-1%	-$2.75K	0.04%	317
2024 Q4	$290K	Sell	12,816 -1,550	-11%	-$37.2K	0.05%	305
2024 Q3	$354K	Sell	14,366 -112	-0.8%	-$2.73K	0.08%	222
2024 Q2	$335K	Buy	14,478 +415	+3%	+$9.71K	0.08%	217
2024 Q1	$339K	Buy	14,063 +808	+6%	+$18.9K	0.09%	195
2023 Q4	$305K	Buy	13,255 +2,465	+23%	+$49.5K	0.07%	232
2023 Q3	$220K	Sell	10,790 -2,572	-19%	-$57.7K	0.05%	284
2023 Q2	$312K	Sell	13,362 -1,896	-12%	-$45.5K	0.07%	223
2023 Q1	$355K	Buy	+15,258	New	+$382K	0.1%	194

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Consolidated Portfolio Review Corp's IDNA Position: Q2 2025 in Review

Consolidated Portfolio Review Corp sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q2 2025, closing a stake of 12,693 shares — an estimated $260K sold.

Consolidated Portfolio Review Corp first reported a position in IDNA in Q1 2023 and held it in 9 quarters. The position peaked at $355K in Q1 2023. 47 funds tracked by Wall St. Rank hold IDNA as of Q2 2025.

Consolidated Portfolio Review Corp reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q2 2025 after selling out during the quarter.
Consolidated Portfolio Review Corp sold 12,693 iShares Genomics Immunology and Healthcare ETF shares in Q2 2025, an estimated $260K.
Consolidated Portfolio Review Corp first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2023 and held it in 9 quarters.
Consolidated Portfolio Review Corp's iShares Genomics Immunology and Healthcare ETF position peaked at $355K in Q1 2023.
47 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q2 2025, filed 18 Jul 2025.